Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide [1] . 5-Fluorouracil (5-FU) is generally administered for treating advanced colorectal cancer. However, the fact that some patients develop 5-FU resistance during the course of treatment is a major obstacle to effective therapy. Therefore, identifying the molecular mechanism is urgently needed to underlie the 5-FU resistance in CRC cells and develop novel diagnostic and prognostic biomarkers for 5-FU resistance that will improve the development of therapeutic strategies for CRC patients [2] .
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MicroRNAs are a set of newly discovered, non-coding small RNA molecules that target mRNA cleavage or translational repression through binding to the sequences on the 3′ untranslated region (3′UTR) of target mRNAs with complete or incomplete complementarity. MiRNAs significantly can act as oncogenes or tumor suppressors and play important roles in diverse biological processes of cancer, including tumor initiation, tumor progression, and chemoresistance [3] . A large number of miRNAs are considered to be dysregulated in CRCs, and some have involved in response to anti-cancer therapies through the regulation of drug metabolism, drug transport, DNA damage response, or cell apoptosis [4] . Prominently, a subset of miRNAs could act as non-invasive and potential predictive biomarkers in circulation for drug response. In this regard, several studies have shown that miR-200c is also involved in inhibiting the development of drug resistance in cancer cells [5] . However, the molecular mechanism as to how miR-200c modulates the chemosensitivity to 5-FU in colorectal cancer is poorly known.
The evidence suggests that inhibition of miR-200c expression results in cancer cell resistance to chemotherapeutic drugs [6] . Studies have shown that miR-200c can potentially sensitize colorectal cancer cells to 5-FU and serves by inhibiting Bcl-2 expression and inducing apoptotic susceptibility to 5-FU [7] .
Toden et al. demonstrated that curcumin chemosensitizes CRC cells to 5-FU via the upregulation of miR-200c in 5-fluorouracil-resistant (5FUR) cancer cell lines [8] .
miR-200c inhibits epithelial-to-mesenchymal transition (EMT), proliferation, metastasis, and resistance to chemotherapeutic drugs and is also significant in the development of drug resistance of cancer cells [9, 10] .
Tanaka et al. have suggested that the downregulated expression of miR-200c plays a role in selective resistance to chemotherapeutic drugs and EMT in CRC cells during repeated treatments with chemotherapeutic drugs [11] .
Our recent study has shown that the inhibition of miR-200c correlated with the acquired resistance of colorectal cancer cells (HCT-116) to 5-FU. We investigated the effect of miR200c inhibition on apoptosis and the expression of PTEN and E-cadherin protein. Our results showed that LNA-anti-miR200c suppressed the expression of miR-200c, PTEN, and Ecadherin compared with the control cells. Furthermore, we observed that LNA-anti-miR-200c could promote cell proliferation through inhibition of caspase 3 activity and reduction of apoptosis that is mediated by PTEN expression [12] .
In conclusion, we hypothesized that miR-200c could be candidate as a therapeutic tool for increasing 5-FU chemosensitivity in CRC. Thus, if the results confirm our hypothesis, miR-200c might be a possible biomarker to predict the response of colorectal cancer to 5-FU-based chemotherapy.
